Investors Shareholders

About
Teams
Sustainability
Investments
Media

Current portfolio

Nkarta

US biotech company developing engineered natural killer (NK) cell therapies

Sector
Healthcare
Country
United States
Fund
LSP 6
Entry
2019
Web
nkartatx.com

Sector
Healthcare
Country
United States
Fund
LSP 6
Entry
2019
Web
nkartatx.com

Latest news

25 September 2023
EQT Private Equity to sell LimaCorporate, one of the global leaders in joint replacement solutions
13 September 2023
Francesco Starace appointed as chair of the Science Based Targets initiative
06 September 2023
Tom Livelli joins EQT Exeter as Partner to co-head EQT Exeter’s multi-family and living strategies in Europe
24 August 2023
BPEA EQT exits Coforge, a multinational Digital IT Solutions & Technology Consulting Services provider
23 August 2023
EQT Growth leads USD 85 million investment round into global corporate wellness platform Gympass

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news

Regulatory News

EQT News

Preferred languageEnglishSwedish

Email address

Offices

Europe
North America
- New York
- San Francisco
APAC

About

EQT Playbook
Fund investors
Purpose and Culture
EQT Foundation
- EQT Foundation
Careers
- Life at EQT
- EQT Academy
Motherbrain

Teams

Roles

Sustainability

Future-proofing

Business Segments

Private Capital
Real Assets

Investments

Portfolio

Shareholders

About EQT AB Group
IPO on Nasdaq Stockholm
Reports and Presentations
Corporate Governance
About the Share

Media

Newsroom
- News
- Reports and presentations

Contact

Media
- Press Contact
Follow

Legal

Sustainable Finance Disclosure
Complaints Handling Procedure
Glossary and Definitions
Policies
Cookie Policy
Terms and Conditions

About

Teams

Sustainability

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180